Intuitive Surgical
ISRG (NASDAQ)
Intuitive Surgical (ISRG) stands out as a leader in robotic-assisted surgery with its innovative da Vinci system and the expanding Ion biopsy tool. Despite experiencing a 1-year return of -6.36%, the company has delivered an impressive 67.63% return over the past five years, indicating strong long-term growth potential. Analysts maintain a consensus rating of "buy," with a median price target of $618, reflecting confidence in the company’s future, particularly as it anticipates a 13.5% to 15.5% growth in da Vinci procedures by 2026.
Pros:
- Leader in robotic-assisted surgery
- Strong 5-year return
Cons:
- Negative 1-year return
- Market volatility risk
Intuitive Surgical (ISRG) may be suitable for long-term investors seeking exposure to the growing field of robotic-assisted surgery, particularly those who can tolerate short-term volatility. With a solid five-year performance and a positive outlook from analysts, this investment could appeal to those looking for potential growth in a pioneering healthcare technology company.